Table 1

Relationship of HER-2/neu overexpression and clinicopathological parameters in prostate cancer (n = 83) and hormone naïve prostate cancer (n = 45)

ParameterHER-2-negativeHER-2-positiveTotalP
#%#%
Prostate cancer
 Total5161.53238.583
 Path stage
  pT23366173450
  ≥pT318551545330.36
 Pretreatment PSA
  <103376102443
  ≥1018452255400.011a
 Ki index
  <20%4563263771
  ≥20%654546110.74
 Hormone status
  Neoadjuvant1133236734
  Naïve368092045<0.0001
Hormone naïve prostate cancer
 Gleason score
  <7238251828
  ≥71414323170.071
 Path stage
  <T2248641428
  ≥T31271529170.265
 Pretreatment PSA
  <10289031031
  ≥10857643140.003a
 Ki index
  <20328271839
  ≥2046723360.583
  • a P generated from the Wald test using SAS procedure LOGISTIC where PSA is a continuous variable.